Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | HPGD | P15428 | 4/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 9/20 | 0.54 |
| ▸ | LMNA | P02545 | 7/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL263250 | 0.85 | TP53 (0.72) | ALDH1A1HPGDGAANPSR1KDM4E | |
| SCHEMBL7014969 | 0.83 | HPGD (0.58) | ALDH1A1HPGDGAANPSR1KDM4E | |
| SCHEMBL5527931 | 0.81 | HTR1A (0.69) | ALDH1A1HPGDGAANPSR1KDM4E | |
| SCHEMBL7012057 | 0.76 | HTR1A (0.61) | HPGDGAAHTR1AHTR7 | |
| SCHEMBL7012098 | 0.75 | RXFP1 (0.54) | ALDH1A1HPGDGAAKDM4ERXFP1 | |
| SCHEMBL7014231 | 0.73 | HTR1A (0.63) | HTR1AHTR7 | |
| SCHEMBL7013844 | 0.73 | HTR1A (0.62) | ALDH1A1HPGDGAATHRBHTR1A | |
| SCHEMBL7012872 | 0.73 | HTR1A (0.62) | GAAKDM4ERXFP1HTR1AHTR7 | |
| SCHEMBL7014563 | 0.73 | HTR1A (0.53) | HPGDHTR1AHTR7 | |
| Hydrochloric Acid SCHEMBL7722346 | 0.73 | HPGD (0.48) | ALDH1A1HPGDGAAKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133998-B2 | Bicyclic pyrimidine derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2012-03-13 | — | — | US | claimed |
| WO-2008138126-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-11-20 | — | — | WO | claimed |
| US-20080280900-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-11-13 | — | — | US | claimed |
| US-8133998-B2 | Bicyclic pyrimidine derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2012-03-13 | — | — | US | disclosed |
| US-8133998-B2 | Bicyclic pyrimidine derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2012-03-13 | — | — | US | disclosed |
| US-8133998-B2 | Bicyclic pyrimidine derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2012-03-13 | — | — | US | disclosed |
| WO-2008138126-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-11-20 | — | — | WO | disclosed |
| US-20080280900-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-11-13 | — | — | US | disclosed |
| US-20080280900-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-11-13 | — | — | US | disclosed |
| US-20080280900-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280900-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1G, RYR1 | ALDH1A1 3805/4885HPGD 1832/4885GAA 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.